The purpose of this multi-center, open label, single arm, post-marketing surveillance study
is to assess the safety of Travacom in patients with open-angle glaucoma or ocular
hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other
intraocular pressure-lowering (IOP) medication and when use of Travacom is considered
appropriate.